Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus reduced tacrolimus versus standard tacrolimus in living donor liver transplant recipients
2010-024527-25Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2013
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in hepatic disease comparing Everolimus plus reduced tacrolimus with Standard tacrolimus (2 arms). Primary endpoint: Composite efficacy failure at 12 months. Started May 2013; status: completed.
02
Drugs
everolimustacrolimus
03
Conditions
hepatic disease
Beyond the preview
Go deeper on 2010-024527-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024527-25.